BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30433832)

  • 1. Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.
    Stahl RA; Reinhard L; Hoxha E
    Expert Rev Clin Immunol; 2019 Feb; 15(2):165-175. PubMed ID: 30433832
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy.
    von Haxthausen F; Reinhard L; Pinnschmidt HO; Rink M; Soave A; Hoxha E; Stahl RAK
    Front Immunol; 2018; 9():3035. PubMed ID: 30619370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Membranous glomerulonephritis : An example of individualized medicine in nephrology].
    Stahl RAK; Hoxha E
    Internist (Berl); 2019 May; 60(5):440-449. PubMed ID: 30859275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.
    Zhang P; Huang W; Zheng Q; Tang J; Dong Z; Jiang Y; Liu Y; Liu W
    J Immunol Res; 2021; 2021():8163298. PubMed ID: 34337081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.
    Tomas NM; Hoxha E; Reinicke AT; Fester L; Helmchen U; Gerth J; Bachmann F; Budde K; Koch-Nolte F; Zahner G; Rune G; Lambeau G; Meyer-Schwesinger C; Stahl RA
    J Clin Invest; 2016 Jul; 126(7):2519-32. PubMed ID: 27214550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
    Tomas NM; Beck LH; Meyer-Schwesinger C; Seitz-Polski B; Ma H; Zahner G; Dolla G; Hoxha E; Helmchen U; Dabert-Gay AS; Debayle D; Merchant M; Klein J; Salant DJ; Stahl RAK; Lambeau G
    N Engl J Med; 2014 Dec; 371(24):2277-2287. PubMed ID: 25394321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membranous Nephropathy: Core Curriculum 2021.
    Alsharhan L; Beck LH
    Am J Kidney Dis; 2021 Mar; 77(3):440-453. PubMed ID: 33487481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranous nephropathy: integrating basic science into improved clinical management.
    Cattran DC; Brenchley PE
    Kidney Int; 2017 Mar; 91(3):566-574. PubMed ID: 28065518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
    Zaghrini C; Seitz-Polski B; Justino J; Dolla G; Payré C; Jourde-Chiche N; Van de Logt AE; Booth C; Rigby E; Lonnbro-Widgren J; Nystrom J; Mariat C; Cui Z; Wetzels JFM; Ghiggeri G; Beck LH; Ronco P; Debiec H; Lambeau G
    Kidney Int; 2019 Mar; 95(3):666-679. PubMed ID: 30784662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular disease: thrombospondin type-1 domain-containing 7A-a new player in membranous nephropathy.
    Allison SJ
    Nat Rev Nephrol; 2015 Feb; 11(2):63. PubMed ID: 25447129
    [No Abstract]   [Full Text] [Related]  

  • 11. PLA2R and THSD7A: Disparate Paths to the Same Disease?
    Beck LH
    J Am Soc Nephrol; 2017 Sep; 28(9):2579-2589. PubMed ID: 28674044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.
    Ghiggeri GM; Seitz-Polski B; Justino J; Zaghrini C; Payré C; Brglez V; Dolla G; Sinico A; Scolari F; Vaglio A; Prunotto M; Candiano G; Radice A; Bruschi M; Lambeau G;
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1762-1776. PubMed ID: 33257410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.
    Pozdzik A; Brochériou I; David C; Touzani F; Goujon JM; Wissing KM
    Biomed Res Int; 2018; 2018():6281054. PubMed ID: 29511687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
    Gödel M; Grahammer F; Huber TB
    N Engl J Med; 2015 Mar; 372(11):1073. PubMed ID: 25760365
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.
    Meyer-Schwesinger C; Lambeau G; Stahl RA
    N Engl J Med; 2015 Mar; 372(11):1074-5. PubMed ID: 25760364
    [No Abstract]   [Full Text] [Related]  

  • 16. [Membranous nephropathy: Pathophysiology and natural history].
    Seitz-Polski B; Lambeau G; Esnault V
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of phospholipase A
    Yeter HH; Isik Gonul I; Eraslan E; Karacalik C; Ogut B; Guz G
    Clin Exp Nephrol; 2021 May; 25(5):488-500. PubMed ID: 33459908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1.
    Schlumberger W; Hornig N; Lange S; Probst C; Komorowski L; Fechner K; Dähnrich C; Stöcker W
    Autoimmun Rev; 2014 Feb; 13(2):108-13. PubMed ID: 24075959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Primary Membranous Nephropathy.
    Gu Y; Xu H; Tang D
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is primary membranous nephropathy a complement mediated disease?
    Reinhard L; Stahl RAK; Hoxha E
    Mol Immunol; 2020 Dec; 128():195-204. PubMed ID: 33142137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.